Focal Segmental Glomerulosclerosis (FSGS) is a devastating clinical condition with defined glomerular histopathology and yet a multifaceted pathophysiological, histological, and […]
Author: Kurt Herpel
Delta4 at BIO-EUROPE 2021
From October 25-28 Delta4 attended the (virtual) BIO-EUROPE conference, the largest partnering event in Europe dedicated to the global biotechnology […]
Delta4 Announces Dr. Hans Lehrach to Join Scientific Advisory Board
VIENNA, Austria, September 27th, 2021 — Delta4, a digital drug discovery company focusing on the identification of new indications for […]
FSGS and COVID-19 programs ready for Phase II studies
We are proud to announce further progress in our current drug discovery and development programs. In late 2020, Delta4 filed […]
Delta4 files four patent applications in FSGS and COVID-19
We are very pleased to announce that Delta4 has filed four patent applications for compounds and combinations of compounds in […]
Sachs 20th Annual Biotech In Europe Forum
The 20th Annual Biotech in Europe (BEF) Forum is recognized as the leading international Stage for those interested in investing […]
World Orphan Drug Congress
With over 1,500 attendees from 50+ countries, the 2020 edition of the World Orphan Drug Congress USA was held online […]
LSX Investival
Delta4 Reflects on the 2020 LSX Investival Showcase: A Landmark Event in Life Sciences Innovation In November 2020, the prestigious […]
Life-Science Investment Days, Vienna
Delta4 Attends the Life Science Investment Days Event of 2019 The Life Science Investment Days event held in Vienna from […]
Biotech in Europe Forum (BEF)
Delta4’s Participation at the 19th Annual Biotech in Europe Forum: A Landmark Experience Delta4 was honored to attend the 19th […]